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Generation of Antibodies of Distinct Subclasses and
Specificity Is Linked to H2s in an Active Mouse Model
of Epidermolysis Bullosa Acquisita
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Misa Hirose1, Michael Kasperkiewicz1, Norito Ishii1,3, Enno Schmidt1, Ju¨rgen Westermann2, Detlef Zillikens1
and Saleh M. Ibrahim1
Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering disease, characterized by antibodies to type
VII collagen (COL7). EBA can be induced in mice by immunization with a fragment of the non-collagenous 1
domain of murine COL7. Contrary to other autoimmune diseases, e.g., rheumatoid arthritis, little is known
about the genetic susceptibility for EBA. We therefore used the EBA mouse model to address the hypothesis
that disease induction depends on the major histocompatibility complex (MHC) haplotype. Mice from different
inbred strains were immunized with recombinant murine COL7. Five distinct responses were observed:
induction of (i) severe disease in SJL/J (H2s) and female MRL/MpJ (H2k), (ii) mild and transient disease in C57Bl/
10.s (H2s), (iii) microscopic blistering in DBA/1J (H2q), (iv) only presence of non-pathogenic autoantibodies in
C57Bl/6J (H2b), NZM2410/J (H2z), BXD2 (H2b), and male MRL/MpJ, and (v) complete resistance to EBA in NOD/
ShiLtJ (H2g7) and C57Bl/10.q (H2q) mice. Overall, susceptibility to EBA was strongly associated with H2s. In
addition, the diseased phenotype was associated with autoantibodies to specific regions of COL7. Our findings
show that induction of antibodies with a distinct specificity is linked to the MHC haplotype in experimental EBA.
Furthermore, our data are the basis for future studies with the goal of identifying non-MHC EBA susceptibility
genes.
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INTRODUCTION
The murine major histocompatibility complex (MHC) locus,
H2, was identified and termed for its role in histocompati-
bility (Snell, 1964). The human MHC, or human leukocyte
antigen (HLA) region, was named according to its original
demonstration on the surface of white blood cells (Dausset,
1958). In 1981, the central importance of these antigens
in immune response was recognized (Benacerraf, 1981).
The MHC is one of the most extensively studied regions in
the genome, because of the contribution of multiple variants
at this locus in inflammatory diseases, including autoimmune
disorders (Satsangi et al., 1996; Harbo et al., 2004; Fernando
et al., 2008). In contrast to most autoimmune diseases,
little is known about susceptibility genes in autoimmune
bullous skin diseases (ABSDs). This heterogeneous group of
disorders is characterized by circulating and tissue-bound
antibodies to structural components of the skin and mucous
membranes (Zillikens, 2009). ABSDs are prototypes of
organ-specific autoimmune disorders. Autoantibodies in
ABSDs are directed to distinct antigens, and pathogenic
relevance of these autoantibodies has been demonstrated in
several of the diseases (Sitaru and Zillikens, 2005; Bieber
et al., 2009). Epidermolysis bullosa acquisita (EBA) is an
ABSD characterized by autoantibodies to type VII collagen
(COL7), the major component of anchoring fibrils (Woodley
et al., 1984, 1988). Epitopes recognized by the majority of
EBA sera were mapped to the non-collagenous 1 domain
of type VII collagen (Woodley et al., 1988; Remington
et al., 2008).
Studies on the genetic basis of ABSDs in patients were
inconsistent, varied considerably between different popula-
tions, and were based on small patient numbers. Pemphigus
vulgaris was found to be associated with HLA-DRW4 in
a Jewish cohort (Park et al., 1979), HLA-DQw1 and -DQw3
polymorphisms in Ashkenazi Jews (Szafer et al., 1987),
HLA-DRB1*04 and DRB1*1401 in Iranian patients (Shams
et al., 2009), HLA-DRB1*0402 haplotypes in Venezuelan
patients (Saenz-Cantele et al., 2007), HLA-DQB1*0503
or DRB1*1405 in Japanese patients, and HLA-B38(35) and
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HLA-Bw55 in an American cohort. For bullous pemphigoid,
MHC association studies have also not been conclusive
(Delgado et al., 1996; Okazaki et al., 2000). In 29 patients
with EBA, an association with HLA-DR2 has been
described (Gammon et al., 1988). Interestingly, in dermatitis
herpetiformis, a disorder associated with gluten-sensitive
enteropathy and IgA antibodies to epidermal and tissue
transglutaminase (Sardy et al., 2002), a strong association
with HLA-DQ2 and HLA-DQ8 has been reported (Spurkland
et al., 1997).
Studies on genetic susceptibility using animal models for
ABSDs are also rare, as most models use the passive transfer of
autoantibodies into mice (Bieber et al., 2009). On the basis of a
strong association of dermatitis herpetiformis with HLA-DQ2
and HLA-DQ8 (Spurkland et al., 1997), autoimmune-prone
NOD/ShiLtJ mice were crossed with DQ8þ mice, lacking
endogenous mouse MHC II, to generate congenic NOD/ShiLtJ
DQ8þ mice. Development of gluten-dependent blistering,
associated with IgA deposition along the dermal–epidermal
junction (DEJ), was observed in 16% of mice, immunized with
crude gluten. No blistering or IgA deposition was seen in NOD/
ShiLtJ or DQ8 congenic mice after gluten sensitization,
indicating that both DQ8 and the NOD/ShiLtJ background
are required for blister formation (Marietta et al., 2004).
To further clarify the relevance of MHC association in
ABSDs, in this study we used a recently established active
mouse model for EBA, which reproduces the inflammatory
form of human EBA. This model appeared to be particularly
suitable to address this question, as repetitive immunizations
with a recombinant fragment of the NC1 domain of COL7
lead to loss of tolerance in 82% of SJL/J, 56% of BALB/c mice,
and 45% of FcgRIIB-deficient mice on the C57Bl/6J genetic
background, but not in outbred SKH-1 mice. In this model,
induction of complement-fixing autoantibodies against COL7
was associated with clinical disease (Sitaru et al., 2006). In
addition, we have previously shown that a single immuniza-
tion is sufficient to trigger the disease in over 95% of SJL/J
mice (Ludwig et al., 2008), but fails to induce disease in
BALB/c mice (unpublished data).
We therefore hypothesized that the MHC haplotype
controls tolerance to COL7. To challenge this assumption,
experimental EBA was induced in several inbred mouse
strains. Clinical phenotype, histological characteristics, and
immunological response were evaluated subsequently. As
MHC governs the presentation of antigen (Miller et al., 1976),
we also hypothesized that development of clinical EBA is
associated with autoantibodies recognizing specific epitopes
within the murine COL7.
RESULTS
H2s haplotype confers susceptibility to clinical EBA
development
We hypothesized that the MHC haplotype controls tolerance to
COL7. To address this assumption, experimental EBA was
induced in different strains of inbred mice by immunization
with a recombinant fragment of murine COL7. Overall, we
observed three distinct clinical responses: (i) induction of
severe disease in SJL/J mice of both sexes (H2s) and in female
MRL/MpJ mice (H2k), (ii) induction of a mild and mostly
transient disease in C57Bl/10.s mice (H2s), and (iii) resistance
to EBA induction in all other strains of mice (Figure 1, Table 1).
Overall, 11 out of 11 SJL/J mice (H2s) developed EBA during
the 10-week observation period. Clinical EBA lesions were
observed at 4 weeks after immunization, and disease severity
increased during the observation period. In C57Bl/10.s mice,
disease severity was significantly lower compared with that
in SJL/J mice, and was transient in most mice (P¼0.001
and 0.015, for weeks 4 and 6, respectively; rank-sum test—no
significant difference was observed at weeks 8 and 10, but
disease incidence was too low in C57Bl/10.s mice to allow
final conclusions). Immunized female MRL/MpJ mice were also
susceptible to EBA induction. In contrast to SJL/J and C57Bl/
10.s mice, disease developed 8 weeks after immunization.
Clinical scores in female MRL/MpJ mice were comparable to
the ones observed in SJL/J mice. All other tested strains were
resistant to EBA induction. The association of H2s with EBA
was statistically significant (Po0.001, w2). In summary, 75% of
mice carrying the H2s haplotype developed clinical EBA. In
contrast, only 5% of mice with other haplotypes developed
disease (Figure 1a, Tables 1 and 2).
In accordance with the clinical observation, microscopic
blistering, determined by hematoxylin and eosin staining of ear
specimen obtained at the end of the observation period, was
evident in 8 of 11 SJL/J, 5 of 11 C57Bl/10.s, and 4 of 4 female
MRL/MpJ mice (Figure 1b). In addition, 3 of 10 DBA/1J mice
revealed microscopic but not macroscopic blistering. All other
strains showed no evidence of microscopic blistering and
leukocyte infiltration (Table 2). By direct immunofluorescence
(IF) microscopy, deposition of IgG was noted in all strains, with
the exception of C57Bl/10.q and NOD/ShiLtJ mice. The rate of
complement deposition at the DEJ was highest in SJL/J, female
MRL/MpJ, DBA/1J, and C57Bl/10.s mice (100%, 100%, 75%,
and 71%, respectively; Table 2).
Levels of complement-fixing autoantibodies at the DEJ correlate
with subepidermal blister formation
On the basis of clinical, histopathological, and immunopatho-
logical findings, five distinct responses to immunization with
mCOL7C can be distinguished: (i) induction of severe EBA, (ii)
induction of a mild and mostly transient disease, (iii) induction
of microscopic blistering, (iv) induction of non-pathogenic
autoantibodies, and (v) resistance to produce anti-mCOL7C
antibodies. In line with previous findings (Sitaru et al., 2006),
subepidermal blistering was associated with a predominant
deposition of complement-fixing IgG2a and IgG2b antibodies at
the DEJ in mice with C3 deposition at the DEJ, whereas IgG1
was preferentially detected in mice without C3 deposition
(Figure 2, Table 2). Interestingly, disease-prone female MRL/MpJ
mice showed a predominant IgG1 response. However, a strong
C3 deposition was observed at the DEJ.
Autoantibodies from mice with clinical disease react with
distinct peptides within the NC1 domain of murine COL7
As the MHC haplotype greatly controls susceptibility to EBA
development, we hypothesized that autoantibody response is
directed to separate epitopes in different strains of mice. To
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address this, IgG reactivity to 20 overlapping peptides
spanning the entire region of murine NC1 amino acids
757–967 (mCOL7C) from mice immunized with mCOL7C
was assessed using enzyme-linked immunosorbent assays.
The cutoff for each peptide was defined as the mean OD450
using serum from healthy SJL/J mice (n¼8). With the
exception of peptide 4 (0.07), peptide 17 (0.09), and peptide
18 (0.15), the cutoff was o0.06. Using analysis of variance
(ANOVA), the reactivity of serum from immunized mice to
each peptide was compared with that of unimmunized
control mice. We observed a broad spectrum of epitopes
recognized by autoantibodies from mice that had developed
anti-COL7-specific antibodies (Figure 3). However, autoanti-
body specificity in mice prone to develop clinical disease had
a distinct profile. Only disease-prone SJL/J and C57Bl/10.s
mice developed antibodies to peptides 1, 7, and 8. With the
exception of DBA/1J and male MRL/MpJ mice, none of the
other tested strains developed antibodies with this specificity.
In disease-prone female MRL/MpJ mice, antibody response
was restricted to peptides 1 and 20. This response toward
peptide 1 in female MRL/MpJ mice was significantly higher
compared with that of male mice of the same strain. In
contrast to SJL/J and C57Bl/10.s mice, DBA/1J mice, prone
to microscopic blistering, had developed reactivity to
peptides 7 and 8, but not to peptide 1.
No evidence of intramolecular and intermolecular epitope
spreading in diseased mice
Intramolecular and intermolecular epitope spreading has
previously been observed in several human autoimmune
blistering skin diseases, and its importance in pathogenicity
has been documented for endemic pemphigus foliaceus
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Figure 1. Immunization with mCOL7C leads to different clinical phenotypes and immunological responses in various strains of mice. (a) Representative
clinical phenotypes from the three different strains are shown. (b) Hematoxylin and eosin (H&E)-stained sections showed subepidermal blistering accompanied
by leukocyte infiltration only in those strains that developed clinical lesions. In contrast, all other strains, with the exception of DBA/1J mice, did not develop
microscopic blistering. Clinical or microscopic evidence of epidermolysis bullosa acquisita (EBA) was associated with complement activation along the
dermal–epidermal junction. Mice without microscopic or clinical EBA either developed non-complement-binding antibodies (C57Bl/6, NZM2410/J, BXBD/TyJ,
and male MRL/MpJ mice), or were completely protected from the development of an autoimmune response (NOD/ShiLtJ and C57Bl/10.q mice). Shown are
representative images corresponding to the underlined mouse strain. Bar¼100 mm.
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(Li et al., 2003). To explore the relevance of intramolecular
epitope spreading in experimental EBA, sera from diseased
SJL/J mice (10 weeks after the initial immunization) were
preadsorbed using mCOL7C-GST, followed by indirect IF
microscopy on normal mouse skin. In all tested samples,
ability to bind to the skin was lost after preadsorption with
mCOL7C-GST (Figure 4a). Similar results were obtained
using less-diluted serum samples (1:100, data not shown). To
confirm the results from indirect IF microscopy, we con-
ducted similar experiments using mouse dermal extract as a
substrate. In line, preadsorbtion of sera from diseased SJL
mice completely inhibited binding at 290kDa (Figure 4b).
Overall, this indicates that epitope spreading to regions
outside the mCOL7C does not occur in experimental EBA
within the observed time period. In transiently diseased
C57Bl/10.s mice, fine epitope mapping was performed at
weeks 4, 6, and 8, in addition to week 10, to investigate a
possible intramolecular epitope spreading. Yet, we observed
no epitope spreading outside the mCOL7C peptide, and no
loss of reactivity with epitopes during the observation period
(data not shown).
DISCUSSION
Recently, two animal models for EBA have been developed,
recapitulating the inflammatory form of the human disease.
Experimental EBA can be induced by repeated injection of
rabbit or human antimouse COL7 IgG into adult mice (Sitaru
et al., 2005; Woodley et al., 2005, 2006). These antibody-
transferring (‘‘passive’’) mouse models of EBA allow the inv-
estigation of mechanisms involved in autoantibody-induced
Table 1. Differences in disease severity in EBA-susceptible strains
Incidence of EBA and clinical score
Week 4 Week 6 Week 8 Week 10
Strain MHC Incidence Score Incidence Score Incidence Score Incidence Score
SJL/J H2s 11/11 3.3±0.6 11/11 3.3±0.9 11/11 3.7±1.0 11/11 4.0±1.2
C57Bl/10.s H2s 6/11 1.8±0.4 5/11 2.0±0.7 3/11 2.7±1.5 2/11 4.0±1.4
MRL/MpJ (f) H2k 0/4 NA 0/4 NA 3/4 2.7±0.6 3/4 3.0±1.0
Abbreviations: EBA, epidermolysis bullosa acquisita; MHC, major histocompatibility complex; NA, not applicable.
EBA induction and clinical evaluation was performed as described in Materials and Methods. After immunization, a severe EBA was induced in SJL/J mice.
In addition, disease severity increased during the observation period. In contrast, compared with SJL/J, C57Bl/10.s mice showed significantly lower disease
activity, and the induced EBA was transient. Female MRL/MpJ mice were also susceptible to EBA induction, however, in contrast to the other two strains,
clinical lesions started to develop with a 4-week delay. All other strains, including DBA/1J (H2q, n=10), NZM2410/J (H2z, n=7), male MRL/MpJ (H2k, n=5),
NOD/ShiLtJ (H2g7, n=10), C57Bl/10.q (H2q, n=10), BXBD/TyJ (H2b, n=8), and C57Bl/6J (H2b, n=10) mice, were resistant to EBA induction. The indicated
score is calculated from diseased mice only.
Table 2. H2s confers susceptibility to induction of experimental EBA
Strain H2 Sex Clinical disease
Microscopic
blistering Infiltration MPO (lgll1) DIF C3 DIF IgG
Ratio DIF
(IgG2a+IgG2b)/IgG1
SJL/J s Both 11/11 8/11 2.6±0.2 5.9±4.6 5/5 5/5 10.1±2.9
C57Bl/10.s s Both 7/11 5/11 1.7±0.3 3.8±4.7 5/7 7/7 12.0±5.3
MRL/MpJ k Female 3/4 4/4 2.0±0.4 ND 4/4 4/4 1.7±1.0
k Male 0/5 0/5 0.2±0.2 0.0±0.0 0/5 5/5 2.1±1.0
DBA/1J q Both 0/10 3/10 1.5±0.2 1.5±0.6 4/5 5/5 4.5±2.1
C57Bl/6 b Both 0/10 0/10 0.0±0.0 0.0±0.1 0/5 5/5 1.1±0.6
NZM2410/J z Both 0/7 0/7 0.5±0.3 ND 0/3 3/3 2.4±1.1
BXD2 b Both 0/8 0/8 0.4±0.3 0.0±0.3 0/4 4/4 2.8±0.8
NOD/ShiLtJ g7 Both 0/10 0/10 0.3±0.2 0.0±0.1 0/5 0/5 DIF negative
C57Bl/10.q q Both 0/10 0/10 0.5±0.3 ND 0/3 0/3 DIF negative
Abbreviations: EBA, epidermolysis bullosa acquisita; H&E, hematoxylin and eosin; IF, immunofluorescence; MPO, myeloperoxidase; ND, not done.
Clinical disease scoring was based on the entire body surface area, whereas histopathology evaluation and direct IF microscopy were performed using
individual ears. In contrast to all other strains, which were resistant to EBA induction, 75% of mice carrying the H2s haplotype and all female MRL/MpJ (H2k)
mice developed skin lesions. Degree of neutrophil infiltration (week 10) was assessed by scoring H&E stained sections (Ludwig et al., 2005) and by
determining MPO reactivity using the enzymatic assay described in Materials and Methods. Degree of neutrophils infiltration correlated with MPO levels
(r=0.7, Po0.001, Spearman’s rank order correlation). In the last column, the ratio of IgG2a+IgG2b to IgG1 staining at the dermal–epidermal junction is
displayed. High values point to a predominant IgG2a and IgG2b binding.
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tissue damage; e.g., we have shown that complement
activation by the alternative pathway (Mihai et al., 2007;
Sesarman et al., 2008a), neutrophils (Chiriac et al., 2007),
and reactive oxygen species (Chiriac et al., 2007) are
required to elicit disease. Alternatively, experimental EBA
can be induced by immunization with an immunogenic
peptide from murine COL7 (Sitaru et al., 2006; Ludwig et al.,
2008). In this ‘‘active’’ EBA model, clinical disease was
accompanied by deposition of complement-activating anti-
bodies at the DEJ (Sitaru et al., 2006). We hereby confirm and
extend this finding in several strains of inbred mice. The
observation of an association of clinical disease with
complement-activating antibodies has also been noted in
other autoimmune and chronic inflammatory diseases, such
as collagen-induced arthritis, experimental myasthenia
gravis, experimental autoimmune encephalomyelitis, anti-
red blood cell-induced hemolytic anemia, and vasculitis
(Staines et al., 1990; Ichikawa et al., 1999; Karachunski et al.,
2000; Azeredo da et al., 2002; Baiu et al., 2005).
In addition, we provide evidence that induction of disease
is strongly associated with the MHC haplotype H2s. More
specifically, 75% of mice carrying H2s developed EBA,
whereas this was observed only in 5% of mice with
haplotypes other than H2s. Furthermore, C57Bl/10.s mice
developed EBA, whereas the genetically identical (with the
exception of the MHC) C57Bl/10.q mice were completely
resistant to EBA induction. Our data also point toward genes
outside the MHC that control susceptibility to EBA develop-
ment: (i) Immunization of SJL/J mice led to a severe and
robust disease induction, whereas C57Bl/10.s mice with the
same MHC haplotype developed a mild and transient
disease. (ii) Female, but not male, MRL/MpJ mice were
susceptible to EBA. (iii) Mice lacking the inhibitory Fcg-
recptor IIB on the otherwise EBA-resistant C56Bl/6 (H2b)
genetic background develop blisters (Sitaru et al., 2006).
These observations encourage further investigations to study
the genetic basis of ABSDs in humans. The present data on
genetic susceptibility to autoimmune blistering in human
populations are contradictory and based on relatively small
cohorts (Gammon et al., 1988; Delgado et al., 1996; Banfield
et al., 1998; Okazaki et al., 2000). The observed association
of EBA susceptibility with H2s in experimental EBA strongly
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Figure 2. Staining intensity of complement-fixing autoantibodies at the dermal–epidermal junction correlates with subepidermal blister formation. To further
validate the association of complement-fixing antibodies with development of clinical epidermolysis bullosa acquisita (EBA), we assessed deposition of
complement-fixing IgG2 antibodies, and non-complement-fixing IgG1 antibodies at the dermal–epidermal junction by direct immunofluorescence microscopy.
Staining intensity was determined by ImageJ. (a) With the exception of female MRL/MpJ mice, the ratio of IgG2a and IgG2b to IgG1 binding shows a bias
to IgG2a and IgG2b in mice prone to the development of clinical EBA (SJL/J versus C57Bl/6: P¼ 0.002; C57Bl/10.s versus C57Bl/6: Po0.001; C57Bl/10.s versus
DBA/1J: P¼0.014; analysis of variance (ANOVA), multiple comparisons calculated using Bonferroni). The difference between DBA/1J and C57Bl/6J mice
was not statistically significant. (b) Representative DIF stainings from one SJL/J and C57Bl/6J mouse are shown. Bar¼ 100mm.
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Figure 3. Distinct specificities of autoantibody responses in epidermolysis bullosa acquisita (EBA)-susceptible and -resistant mice. (a) Schematic diagram
of the murine NC1 domain, its subdomains, and the overlapping fragments used for mapping. (b) Reactivity of sera with the 20 overlapping fragments. Displayed
in red are sera that had a statistically significant (analysis of variance (ANOVA)) higher reactivity than did the control serum (normal SJL/J mice). A distinct
reactivity pattern was observed in mice with clinical EBA lesions, which reacted with peptides 1, 7, and 8. (c) Mean±SD reactivity to peptides 1, 7, and 8.
Dotted line indicates the mean reactivity of control serum. *Indicates statistical significance compared with normal SJL/J mice (ANOVA).
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supports the notion that the human disease is also linked with
MHC haplotypes. Likewise, such an association is also obser-
ved in many models of autoimmune or chronic inflammatory
diseases, e.g., in multiple sclerosis/experimental autoimmune
encephalitis, type 1 diabetes, systemic lupus erythematosus,
and rheumatoid arthritis (Gunther et al., 1978; Woodley
et al., 1981; Kotzin and Palmer, 1987; Wicker et al., 1987;
Happ et al., 1988; Fernando et al., 2008). As the observed
gender difference in MRL/MpJ mice regarding the suscept-
ibility toward EBA has not been noted in other mouse strains
and in humans, interpretation of this observation can only be
preliminary. It is most likely restricted to this particular
mouse strain, as female MRL/MpJ mice are also more prone
to develop spontaneous autoimmune pancreatitis (Kanno
et al., 1992).
As the presentation of antigen by MHC is influenced by
the haplotype, and susceptibility to induction of experimental
EBA is associated with the H2s haplotype, we hypothesized
that antibodies to certain epitopes within the NC1 domain of
COL7 preferentially develop in mice prone to disease. The
results of our B-cell epitope mapping using 20mer peptides
covering the mCOL7C fragment confirmed this assumption.
With the exception of female MRL/MpJ mice (reactivity to
peptides 1 and 20), EBA-susceptible mice recognized
peptides P1, P7, and P8, whereas this pattern of reactivity
was not observed in the other strains. Future studies will
address whether these epitopes are indeed pathogenically
relevant. However, epitopes from peptides 7 and 8 are also
recognized by autoreactive T cells in this model (Sitaru et al.,
2010). So far, experimental EBA has been induced using
polyclonal antibodies (Woodley et al., 2005, 2006; Sitaru
et al., 2005; Chen et al., 2007). Characterizing the specificity
of blister-inducing autoantibodies in these mouse models
demonstrated that disease can be induced by polyclonal
antibodies directed against the entire NC1 domain (Woodley
et al., 2005, 2006), as well as more defined regions within
NC1, including the cartilage matrix protein domain and
fibronectin-III-like domains 3, 4, 7, and 8 (Sitaru et al.,
2005). In addition, disease was induced by affinity-purified
polyclonal antibodies to the cartilage matrix protein
domain (Chen et al., 2007). Using an ex vivo model of
EBA, recombinant human autoantibodies binding within
fibronectin-III-like domains 4–6 induced dermal epidermal
separation (Recke et al., 2009b). This seeming discrepancy
between human EBA, with pathogenic relevant epitopes
to the cartilage matrix protein domain (Chen et al., 2007)
and to fibronectin-III-like domains 4–6 (Recke et al., 2009b),
and immunization-induced EBA, with pathogenic anti-
bodies within the fibronectin-III-like domains 7–9, may be
explained by the fact that none of the other epitopes outside
those regions, which are observed at a high frequency in
patients (Lapiere et al., 1993), as well as to autoantibodies
to the NC2 or triple-helical domains (Delgado et al., 1996;
Ishii et al., 2004, 2009), have been tested for pathogenic
relevance.
In addition to the isotype and specificity of autoantibodies,
intramolecular and intermolecular epitope spreading has
been observed in patients with ABSDs (Chan et al., 1998;
Fairley et al., 2004; Recke et al., 2009a). This has been best
demonstrated for endemic pemphigus foliaceus (Li et al.,
2003). Our data suggest that epitope spreading to regions
outside mCOL7C is not required to induce disease in the
active EBA mouse model, as binding of sera to the skin was
completely abolished by preadsorption with mCOL7C.
In summary, in this study we show that (i) susceptibility
to the inflammatory-type EBA is strongly associated with
the H2s haplotype, (ii) genes outside the MHC are likely
to contribute to the disease, (iii) induction of EBA is
accompanied with specific isotypes and autoantibody speci-
ficities, (iv) and epitope spreading does not contribute to EBA
development. Furthermore, our data are the basis for future
studies identifying non-MHC EBA susceptibility genes.
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Figure 4. No evidence of molecular epitope spreading in diseased mice. (a) To study inter- and/or intramolecular epitope spreading, sera from diseased
SJL/J mice were preadsorbed using mCOL7C-GST, and tested for reactivity with skin and dermal extract. Fluorescence intensity at the dermal–epidermal junction
was analyzed using ImageJ (mean±SD). *Indicates statistical significance. Representative stainings are shown below. In all samples, ability to bind to skin
was lost after preadsorption with mCOL7C-GST. This indicates that inter- and intramolecular epitope spreading did not occur in experimental epidermolysis
bullosa acquisita (EBA) within the observed time period. Bar¼ 50 mm. (b) Results from immunofluorescence microscopy inhibition studies were confirmed using
western blotting, with mouse dermal extract as a substrate. d, dermis; e, epidermis; NMS, normal mouse serum.
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MATERIALS AND METHODS
Mice
Mice aged 6–8 weeks were obtained from Charles River (Sulzfeld,
Germany). Animals were maintained on a 12-hour light–dark cycle
at the animal facility of the University of Lu¨beck. Mice were held
under SPF conditions and fed acidified drinking water and standard
chow ad libidum. Protocols were approved by the Animal Rights
Commission of the Ministry of Agriculture and Environment,
Schleswig-Holstein (70-7/08).
Recombinant and synthetic peptides
The immunodominant mCOL7C epitope of the murine NC1 domain
(amino acids 757–967) was produced as glutathionyl-s-transferase
fusion protein using a prokaryotic expression system and purified by
glutathione-affinity chromatography as described (Sitaru et al., 2005,
2006; Sesarman et al., 2008b). For determination of COL7-specific
antibodies by enzyme-linked immunosorbent assays, mCOL7C was
expressed in a similar manner and purified using polyhistidine-tag
(his-mCOL7C). A total of 20 overlapping 20-mer peptides with
N-terminal biotinylation, covering mCOL7C, were synthesized by
JPT Peptide Technologies GmbH (Berlin, Germany; Supplementary
Table S1 online).
Immunization of mice and observation protocol
For induction of an autoimmune response toward murine COL7,
mice were immunized according to a slightly modified protocol
(Sitaru et al., 2006; Bieber et al., 2009). In brief, 60 mg GST-mCOL7C
emulsified in 60ml adjuvant (TiterMax, Alexis, Lo¨rrach, Germany)
was injected subcutaneously into footpads. For each mouse
strain and sex, a minimum of four mice were immunized. Additional
experiments using adjuvants other than TiterMax, including
complete Freund’s adjuvant/incomplete Freund’s adjuvant and
AbISCO-100, have also been conducted. Induction of experimental
EBA is, however, only possible using TiterMax (Supplementary Table
S2 online). The extent of disease, determined by the percentage of
body surface area covered by lesions, was evaluated 4, 6, 8, and 10
weeks after immunization. As described (Sitaru et al., 2006), mice
were assigned a score ranging from 0 to 5, corresponding to 0%,
o1%, X1% to o5%, X5% to o10%, X10% to o20%, and
X20%, respectively. From every mouse, serum and skin samples
were obtained at the end of the 10-week observation period. Serum
was stored at 201C; skin samples were fixed in 4% buffered
formalin and snap-frozen.
Detection of circulating autoantibodies
Circulating autoantibodies were detected by incubating diluted
serum samples on his-mCOL7C-coated plates. To measure serum
levels of antibodies against COL7 or to peptides, enzyme-linked
immunosorbent assays using synthetic or recombinant peptides of
COL7 as target antigens were performed as described, with minor
modifications (Sitaru et al., 2006).
Detection of tissue-bound autoantibodies by direct IF
microscopy
Direct IF microscopy was performed as detailed (Sitaru et al., 2005).
In brief, frozen sections were prepared from tissue biopsy samples
and incubated with goat antimouse antibodies reactive with total IgG,
IgG1, IgG2, IgG3, and murine C3 (Dako, Hamburg, Germany).
Evaluation of neutrophil infiltration
Histopathology: sections from paraffin-embedded tissues were stained
with hematoxylin and eosin. Sections were then semiquantitatively
analyzed by two blinded observers. Infiltration of neutrophils was scored
ranging from 0 to 3, corresponding to no, mild, moderate, or severe
infiltration (Ludwig et al., 2005). Myeloperoxidase assay: neutrophil
infiltration of murine skin was assayed as described (Bradley et al., 1982;
Ludwig et al., 2005). Briefly, the left ear was removed. Myeloperoxidase
was extracted by homogenization in a buffer containing 0.1M Tris-Cl, pH
7.6, 0.15M NaCl, and 0.5% hexadecyl trimethylammoniumbromide
(Sigma, Munich, Germany). Myeloperoxidase activity in the supernatant
fraction was measured by the change in optical density at 460. A
standard reference curve was established using known concentrations of
purified myeloperoxidase (Sigma).
Preparation of dermal extract
Murine dermal extracts were prepared as described for human skin
(Zillikens et al., 1996).
Indirect IF microscopy and inhibition studies
Sera of three different diseased SJL/J mice were analyzed by
indirect IF microscopy on cryosections of murine tail skin at a
dilution of 1:1,000. Antibodies bound to the DEJ were detected by
fluorescein isothiocyanate-conjugated goat antimouse IgG antibo-
dies (Dako). Serum was either directly added to sections or
preincubated with GST-mCOL7C at a concentration of 1 mgml1
for 1 hour at room temperature. Fluorescence intensity at the DEJ
was determined by ImageJ (http://rsbweb.nih.gov/ij/), using dermal
fluorescence for background subtraction. In addition, western blots
were performed with the same sera using mouse dermal extract as a
substrate: mouse sera were diluted 1:50 with 1% bovine serum
albumin/0.05% Tween 20/phosphate-buffered saline. For detection,
enhanced chemiluminescence on X-ray films, together with perox-
idase-coupled polyclonal rabbit antimouse pan-IgG antibody
(Dako), was used. For preadsorption experiments, diluted mouse
sera were preincubated for 30 minutes at room temperature with
100mgml1 mCOL7c:GST and GST, before being applied on
immunoblot membranes.
Statistical analysis
Statistical calculations were performed using SigmaStat (Systat
Software, Chicago, IL). Applied tests are indicated in the respective
table and figure legends. A P-value o0.05 was considered
statistically significant.
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